Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 7
2004 4
2005 6
2006 3
2007 8
2008 4
2009 4
2010 3
2011 12
2012 17
2013 20
2014 20
2015 24
2016 20
2017 14
2018 11
2019 15
2020 20
2021 18
2022 22
2023 14
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

238 results

Results by year

Filters applied: . Clear all
Page 1
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gümüş M, Mar N, Loriot Y, Fléchon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS; EV-302 Trial Investigators. Powles T, et al. N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117. N Engl J Med. 2024. PMID: 38446675 Clinical Trial.
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; KEYNOTE-361 Investigators. Powles T, et al. Lancet Oncol. 2021 Jul;22(7):931-945. doi: 10.1016/S1470-2045(21)00152-2. Epub 2021 May 26. Lancet Oncol. 2021. PMID: 34051178 Clinical Trial.
Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer.
Huang KW, Hsu FF, Qiu JT, Chern GJ, Lee YA, Chang CC, Huang YT, Sung YC, Chiang CC, Huang RL, Lin CC, Dinh TK, Huang HC, Shih YC, Alson D, Lin CY, Lin YC, Chang PC, Lin SY, Chen Y. Huang KW, et al. Among authors: lin yc. Sci Adv. 2020 Jan 15;6(3):eaax5032. doi: 10.1126/sciadv.aax5032. eCollection 2020 Jan. Sci Adv. 2020. PMID: 31998834 Free PMC article.
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.
Kelly WK, Danila DC, Lin CC, Lee JL, Matsubara N, Ward PJ, Armstrong AJ, Pook D, Kim M, Dorff TB, Fischer S, Lin YC, Horvath LG, Sumey C, Yang Z, Jurida G, Smith KM, Connarn JN, Penny HL, Stieglmaier J, Appleman LJ. Kelly WK, et al. Among authors: lin yc. Cancer Discov. 2024 Jan 12;14(1):76-89. doi: 10.1158/2159-8290.CD-23-0964. Cancer Discov. 2024. PMID: 37861461 Free PMC article.
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Balmaña J, Fasching PA, Couch FJ, Delaloge S, Labidi-Galy I, O'Shaughnessy J, Park YH, Eisen AF, You B, Bourgeois H, Gonçalves A, Kemp Z, Swampillai A, Jankowski T, Sohn JH, Poddubskaya E, Mukhametshina G, Aksoy S, Timcheva CV, Park-Simon TW, Antón-Torres A, John E, Baria K, Gibson I, Gelmon KA; LUCY investigators. Balmaña J, et al. Breast Cancer Res Treat. 2024 Apr;204(2):237-248. doi: 10.1007/s10549-023-07165-x. Epub 2023 Dec 19. Breast Cancer Res Treat. 2024. PMID: 38112922 Free PMC article. Clinical Trial.
Alkali metal bilayer intercalation in graphene.
Lin YC, Matsumoto R, Liu Q, Solís-Fernández P, Siao MD, Chiu PW, Ago H, Suenaga K. Lin YC, et al. Nat Commun. 2024 Jan 24;15(1):425. doi: 10.1038/s41467-023-44602-3. Nat Commun. 2024. PMID: 38267420 Free article.
Vapour-liquid-solid growth of monolayer MoS2 nanoribbons.
Li S, Lin YC, Zhao W, Wu J, Wang Z, Hu Z, Shen Y, Tang DM, Wang J, Zhang Q, Zhu H, Chu L, Zhao W, Liu C, Sun Z, Taniguchi T, Osada M, Chen W, Xu QH, Wee ATS, Suenaga K, Ding F, Eda G. Li S, et al. Among authors: lin yc. Nat Mater. 2018 Jun;17(6):535-542. doi: 10.1038/s41563-018-0055-z. Epub 2018 Apr 23. Nat Mater. 2018. PMID: 29686277
Heterodimensional superlattice with in-plane anomalous Hall effect.
Zhou J, Zhang W, Lin YC, Cao J, Zhou Y, Jiang W, Du H, Tang B, Shi J, Jiang B, Cao X, Lin B, Fu Q, Zhu C, Guo W, Huang Y, Yao Y, Parkin SSP, Zhou J, Gao Y, Wang Y, Hou Y, Yao Y, Suenaga K, Wu X, Liu Z. Zhou J, et al. Among authors: lin yc. Nature. 2022 Sep;609(7925):46-51. doi: 10.1038/s41586-022-05031-2. Epub 2022 Aug 31. Nature. 2022. PMID: 36045238
Excitonic Effects in Energy-Loss Spectra of Freestanding Graphene.
Guandalini A, Senga R, Lin YC, Suenaga K, Ferretti A, Varsano D, Recchia A, Barone P, Mauri F, Pichler T, Kramberger C. Guandalini A, et al. Among authors: lin yc. Nano Lett. 2023 Dec 27;23(24):11835-11841. doi: 10.1021/acs.nanolett.3c03863. Epub 2023 Dec 13. Nano Lett. 2023. PMID: 38088831
238 results